BACKGROUND: Indisulam possesses anticancer properties through down-regulation of various cell-cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors. METHODS: The authors designed a phase 2 study of indisulam in combination with idarubicin and cytarabine in patients who had relapsed/refractory acute myeloid leukemia AML and high-risk myelodysplastic syndrome. In stage 1, patients received intravenous indisulam at 400 mg/m2 on days 1 and 8 of a 28-day cycle. If they had no response, then patients received same dose schedule of indisulam followed by intravenous idarubicin 8 mg/m2 daily for 3 days and cytarabine 1.0 g/m2 over 24 hours daily on days 9 through 12 (for those aged < 60 years) or days 9 through 11 (for those aged > 60 years) of a 28-day cycle. Primary endpoints included the overall response rate, and secondary objectives included overall survival. RESULTS: Forty patients were enrolled. Of the 37 evaluable patients, 31 received indisulam with chemotherapy. Of these, 11 (35%) responded for a median duration of 5.3 months. The estimated 1-year overall survival rate was 51% for responders compared with 8 % for nonresponders (P < .001). The most common grade ≥3 nonhematologic toxicities were electrolyte abnormalities (50%) and febrile neutropenia (28%). CONCLUSIONS: The combination of indisulam with idarubicin and cytarabine yielded a 35% response rate in heavily pretreated patients with AML. With emerging data identifying the expression of DCAF15 (DDB1 and CUL4-associated factor 15) as a potential biomarker for activity, the combination of indisulam with idarubicin and cytarabine should be studied in a biomarker-driven trial or in patients who have splicing factor mutations. Cancer 2018;124:2758-65.
BACKGROUND:Indisulam possesses anticancer properties through down-regulation of various cell-cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors. METHODS: The authors designed a phase 2 study of indisulam in combination with idarubicin and cytarabine in patients who had relapsed/refractory acute myeloid leukemiaAML and high-risk myelodysplastic syndrome. In stage 1, patients received intravenous indisulam at 400 mg/m2 on days 1 and 8 of a 28-day cycle. If they had no response, then patients received same dose schedule of indisulam followed by intravenous idarubicin 8 mg/m2 daily for 3 days and cytarabine 1.0 g/m2 over 24 hours daily on days 9 through 12 (for those aged < 60 years) or days 9 through 11 (for those aged > 60 years) of a 28-day cycle. Primary endpoints included the overall response rate, and secondary objectives included overall survival. RESULTS: Forty patients were enrolled. Of the 37 evaluable patients, 31 received indisulam with chemotherapy. Of these, 11 (35%) responded for a median duration of 5.3 months. The estimated 1-year overall survival rate was 51% for responders compared with 8 % for nonresponders (P < .001). The most common grade ≥3 nonhematologic toxicities were electrolyte abnormalities (50%) and febrile neutropenia (28%). CONCLUSIONS: The combination of indisulam with idarubicin and cytarabine yielded a 35% response rate in heavily pretreated patients with AML. With emerging data identifying the expression of DCAF15 (DDB1 and CUL4-associated factor 15) as a potential biomarker for activity, the combination of indisulam with idarubicin and cytarabine should be studied in a biomarker-driven trial or in patients who have splicing factor mutations. Cancer 2018;124:2758-65.
Authors: Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh Journal: Haematologica Date: 2013-10-18 Impact factor: 9.941
Authors: T Owa; H Yoshino; T Okauchi; K Yoshimatsu; Y Ozawa; N H Sugi; T Nagasu; N Koyanagi; K Kitoh Journal: J Med Chem Date: 1999-09-23 Impact factor: 7.446
Authors: K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio Journal: Invest New Drugs Date: 2001 Impact factor: 3.850
Authors: Y Ozawa; N H Sugi; T Nagasu; T Owa; T Watanabe; N Koyanagi; H Yoshino; K Kitoh; K Yoshimatsu Journal: Eur J Cancer Date: 2001-11 Impact factor: 9.162
Authors: R B Walter; M Othus; A K Burnett; B Löwenberg; H M Kantarjian; G J Ossenkoppele; R K Hills; F Ravandi; T Pabst; A Evans; S R Pierce; M-C Vekemans; F R Appelbaum; E H Estey Journal: Leukemia Date: 2014-08-12 Impact factor: 11.528
Authors: W S Siegel-Lakhai; A S Zandvliet; A D R Huitema; M M Tibben; G Milano; V Girre; V Diéras; A King; E Richmond; J Wanders; J H Beijnen; J H M Schellens Journal: Br J Cancer Date: 2008-04-15 Impact factor: 7.640
Authors: Silvia A Teixeira; Mariano S Viapiano; Augusto F Andrade; Mohan S Nandhu; Julia A Pezuk; Lucas T Bidinotto; Veridiana K Suazo; Luciano Neder; Carlos G Carlotti; Aline P Becker; Luiz Gonzaga Tone; Carlos A Scrideli Journal: Mol Neurobiol Date: 2021-06-03 Impact factor: 5.590
Authors: Wei-Ching Chen; Minh D To; Peter M K Westcott; Reyno Delrosario; Il-Jin Kim; Mark Philips; Quan Tran; Saumya R Bollam; Hani Goodarzi; Nora Bayani; Olga Mirzoeva; Allan Balmain Journal: Nat Commun Date: 2021-07-13 Impact factor: 14.919